HCC - HEPATOCELLULAR CARCINOMA
Clinical trials for HCC - HEPATOCELLULAR CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HCC - HEPATOCELLULAR CARCINOMA trials appear
Sign up with your email to follow new studies for HCC - HEPATOCELLULAR CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental drug called DECOY20, given alone or with another drug (tislelizumab), in about 120 adults with advanced solid tumors like liver, colorectal, pancreatic, lung, head and neck, bladder, or MSI-high cancers. The main goals are to check saf…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Indaptus Therapeutics, Inc • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New combo attack shows promise for tough liver tumors
Disease control OngoingThis study looks at a three-part treatment for people with intermediate to advanced liver cancer that cannot be removed by surgery. The treatment combines a procedure to block the tumor's blood supply (TACE), precise radiation (SBRT), and drugs that help the immune system fight c…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Universal CAR-T therapy takes on tough cancers
Disease control TerminatedThis early-phase study tests a new type of immune cell therapy called universal CAR-T cells in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The therapy targets a protein called GPC3 found on these cancer cells. The main goals are to …
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated May 12, 2026 13:43 UTC
-
Immunotherapy combo may boost liver cancer ablation success
Disease control OngoingThis study tests whether giving two immunotherapy drugs (durvalumab and tremelimumab) before a standard liver cancer ablation procedure, followed by durvalumab alone for 11 months, can reduce the chance of cancer coming back. It involves 30 adults with early-stage liver cancer wh…
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Phase: PHASE2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
AI tool aims to catch liver cancer spread earlier
Knowledge-focused OngoingThis study looks at whether a machine learning tool can accurately predict the risk of liver cancer spreading to the lungs or bones in over 1,500 adults. Participants continue their usual care, and doctors decide on any extra scans or tests. The goal is to see if this risk-based …
Matched conditions: HCC - HEPATOCELLULAR CARCINOMA
Sponsor: Tongji Hospital • Aim: Knowledge-focused
Last updated May 11, 2026 20:53 UTC